###begin article-title 0
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trans</italic>
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
Development of a Single Vector System that Enhances Trans-Splicing of SMN2 Transcripts
###end article-title 0
###begin p 1
Conceived and designed the experiments: THC CLL. Performed the experiments: THC MS. Analyzed the data: CLL. Contributed reagents/materials/analysis tools: THC TDB. Wrote the paper: THC CLL. Training for animal injection experiments: MAP.
###end p 1
###begin p 2
###xml 144 151 144 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 259 263 259 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 301 305 301 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 402 403 402 403 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</underline>
###xml 402 407 402 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><underline>t</underline>rans</italic>
###xml 408 409 408 409 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</underline>
###xml 446 450 446 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 563 568 563 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 635 638 635 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 860 868 860 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 965 970 965 970 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 1029 1034 1029 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 1053 1060 1053 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 765 772 <span type="species:ncbi:9606">patient</span>
###xml 827 831 <span type="species:ncbi:10090">mice</span>
RNA modalities are developing as a powerful means to re-direct pathogenic pre-mRNA splicing events. Improving the efficiency of these molecules in vivo is critical as they move towards clinical applications. Spinal muscular atrophy (SMA) is caused by loss of SMN1. A nearly identical copy gene called SMN2 produces low levels of functional protein due to alternative splicing. We previously reported a trans-splicing RNA (tsRNA) that re-directed SMN2 splicing. Now we show that reducing the competition between endogenous splices sites enhanced the efficiency of trans-splicing. A single vector system was developed that expressed the SMN tsRNA and a splice-site blocking antisense (ASO-tsRNA). The ASO-tsRNA vector significantly elevated SMN levels in primary SMA patient fibroblasts, within the central nervous system of SMA mice and increased SMN-dependent in vitro snRNP assembly. These results demonstrate that the ASO-tsRNA strategy provides insight into the trans-splicing mechanism and a means of significantly enhancing trans-splicing activity in vivo.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trans</italic>
###xml 393 396 393 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-GarciaBlanco1">[1]</xref>
###xml 397 400 397 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Zayed1">[6]</xref>
###xml 402 407 402 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trans</italic>
###xml 538 543 538 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 566 569 566 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Wood1">[7]</xref>
###xml 791 796 791 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
Trans-splicing has recently been envisioned as a potential therapeutic intervention for a variety of genetic diseases. The potential effectiveness of this strategy has been demonstrated in a variety of diseases including spinal muscular atrophy, cystic fibrosis, hyper-IgM X-linked immunodeficiency, hemophilia A, Alzheimer's disease, and epidermolysis bullosa simplex with muscular dystrophy [1]-[6]. Trans-splicing is a natural, albeit infrequently utilized process in mammals, therefore, maximizing efficiency is central to developing trans-splicing therapeutics [7]. Conceptually, this strategy relies upon nuclear pre-mRNA splicing occurring between two different molecules: 1) the mutant endogenous RNA and 2) the exogenous therapeutic RNA that provides the correct RNA sequence via a trans-splicing event.
###end p 4
###begin p 5
###xml 97 120 97 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">survival motor neuron 1</italic>
###xml 122 126 122 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 180 183 180 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Crawford1">[8]</xref>
###xml 185 188 185 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Oskoui1">[9]</xref>
###xml 218 221 218 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 234 238 234 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 243 247 243 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 247 251 247 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Lefebvre1">[10]</xref>
###xml 336 340 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 381 385 381 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 471 475 471 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Lefebvre1">[10]</xref>
###xml 606 610 606 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 618 622 618 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Cartegni1">[11]</xref>
###xml 624 628 624 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Lorson1">[12]</xref>
###xml 193 199 <span type="species:ncbi:9606">humans</span>
Spinal Muscular Atrophy (SMA), a neurodegenerative disorder, is caused by the homozygous loss of survival motor neuron 1 (SMN1) and is the leading genetic cause of infantile death [8], [9]. In humans two copies of the SMN gene exist, SMN1 and SMN2[10]. The critical distinction between the two genes occurs at the RNA processing level: SMN1 produces full-length transcripts, while SMN2 primarily produces an alternatively spliced transcript lacking the final coding exon [10]. A single silent C to T non-polymorphic nucleotide difference is responsible for disrupting a critical splice enhancer element in SMN2 exon 7 [11], [12].
###end p 5
###begin p 6
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 105 109 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Sumner1">[13]</xref>
###xml 207 211 207 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 308 313 308 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 372 376 372 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Baughan1">[14]</xref>
###xml 377 381 377 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Marquis1">[20]</xref>
###xml 421 425 421 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 437 444 437 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 500 504 500 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 510 514 510 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Hua2">[18]</xref>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
###xml 473 478 <span type="species:ncbi:10090">mouse</span>
###xml 494 499 <span type="species:ncbi:9606">human</span>
SMN2 is retained in essentially all SMA patients and is a primary target for SMA therapeutic development [13]. In addition to the identification and development of small molecules that stimulate full-length SMN2 expression, RNA modalities such as antisense oligonucleotides (ASO), TOES/bifunctional RNAs and trans-splicing RNAs have shown promise in SMA cell-based models [14]-[20]. ASOs have also been shown to modulate SMN2 expression in vivo in an unaffected transgenic mouse expressing the human SMN2 gene [18].
###end p 6
###begin p 7
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 264 267 264 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 287 292 287 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 303 311 303 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 440 445 440 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 944 951 944 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 792 797 <span type="species:ncbi:10090">mouse</span>
In this report, we demonstrate that trans-splicing efficiency is enhanced by competitively disabling a downstream splice site. As a means to develop a tractable molecular modality, a series of antisense RNAs were screened to identify a sequence that would disable SMN exon 8 and promote trans-splicing. In vitro assays identified an enhancing antisense RNA and were constructed into a novel single vector system individually expressing the trans-splicing RNA and the antisense RNA. Cell-based assays identified a highly efficient vector system that resulted in high levels of trans-splicing and correspondingly high SMN protein levels and increased SMN activity in SMA-derived extracts as measured by snRNP assembly assays. Intracerebroventricular delivery of the ASO-tsRNA vector in the SMA mouse model increases SMN protein in the central nervous system of affected animals, demonstrating a platform that can significantly elevate SMN levels in vivo and in a relevant disease context.
###end p 7
###begin title 8
Results
###end title 8
###begin title 9
###xml 58 67 58 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN trans</italic>
Competitive inhibition of downstream splice site enhances SMN trans-splicing
###end title 9
###begin p 10
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 38 45 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 98 103 98 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 153 162 153 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN trans</italic>
###xml 265 269 265 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Coady1">[15]</xref>
###xml 288 295 288 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 500 507 500 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 245 252 <span type="species:ncbi:9606">patient</span>
The key to introducing trans-splicing in vivo and in clinical settings is by developing efficient trans-splicing systems. We have previously described a SMN trans-splicing system that significantly elevated full-length SMN protein levels in SMA patient fibroblasts [15]. However, initial in vivo experiments failed to achieve similar levels of activation (data not shown). Therefore, we initially examined SMN2 trans-splicing with the goal of devising strategies to enhance trans-splicing efficiency in vivo.
###end p 10
###begin p 11
###xml 3 13 3 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2 trans</italic>
###xml 110 115 106 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 139 148 135 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003468-g001">Figure 1A</xref>
###xml 256 261 252 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 302 306 298 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 396 401 392 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 582 586 578 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 628 637 624 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN trans</italic>
###xml 651 655 647 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-delaMata1">[21]</xref>
###xml 865 870 861 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 972 977 968 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 1041 1046 1037 1042 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 1077 1086 1073 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003468-g001">Figure 1B</xref>
###xml 1105 1109 1101 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1194 1198 1190 1194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1301 1310 1297 1306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN trans</italic>
###xml 1370 1374 1366 1370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1386 1395 1382 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003468-g001">Figure 1C</xref>
###xml 1515 1520 1511 1516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
In SMN2 trans-splicing, there are three potential splicing outcomes: full length (FL), truncated (Delta7) and trans-spliced mRNA (TRANS*) (Figure 1A). Since pre-mRNA splicing is a highly dynamic process, we hypothesized that competition exists between the trans-splicing event and the naturally strong SMN2 exon 8 splice site. Thus, competitive inhibition of the exon 8 splice site would enhance trans-splicing efficiency. To address this possibility, two complementary experiments were performed. A previously described slow-polymerase encoding plasmid was co-transfected with the SMN2 mini-gene and the plasmid expressing the SMN trans-splicing RNA [21]. Under these experimental conditions, the exon 8 3' splice site approximately two kb downstream from exon 7, should not be synthesized as quickly as the natural polymerase, therefore, potentially favoring the trans-splicing event. Consistent with the hypothesis, in the presence of the slow transcribing polymerase, trans-splicing was substantially increased over the typical level of trans-splicing previously observed (Figure 1B). Additionally, a SMN2 mini-gene was used in a separate experiment in which the intervening intron between SMN2 exons 7 and 8 was deleted. In the absence of an intact acceptor site at the intron 7/exon 8 junction, SMN trans-splicing was again elevated several fold over the standard SMN2 mini-gene (Figure 1C). Collectively, these results demonstrate that competitively disabling the downstream splice site can lead to enhanced trans-splicing efficiency, either through a biochemical means or by a genetic alteration.
###end p 11
###begin title 12
###xml 48 51 48 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
Development of a single plasmid vector enhances SMN based trans-splicing.
###end title 12
###begin p 13
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 169 173 169 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 234 239 230 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trans</italic>
###xml 264 268 260 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 582 587 578 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 653 658 649 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 754 756 750 752 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 834 838 830 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1135 1140 1131 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 1208 1212 1204 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 1226 1230 1222 1226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1470 1475 1454 1459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1669 1673 1653 1657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 1685 1689 1669 1673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1704 1708 1688 1692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1708 1716 1692 1696 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;In7</sup>
###xml 1930 1935 1898 1903 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
(A) Proposed ASO-tsRNA mechanism. SMN2 transcripts alternative splice producing two mRNA products. The alternative splicing pathway is represented by gray dashed lines, SMN2 mRNA products: "Delta7"- Exon 7 skipped, "FL"- full length. Trans-splicing RNA identifies SMN2 pre-mRNA intron 6 which overlaps the endogenous branch point then incorporated in the final mRNA is catalyzed by the spliceosome. Circles surrounding symbol "BP" identifies known branchpoints in the model. We demonstrate a novel mechanism of disrupting downstream intron 7 splicing elements causes enhancement of trans-splicing. (Bold "TRANS*" and large black arrow indicate enhanced trans-splicing pathway). The effect is accomplished via enhancing Antisense Oligonucleotides "ASO In711" targeted to the distal intron and exon boundary. The stop codons "STOP" and SMN2 "C-T" or tsRNA "C*" nucleotide changes are denoted with vertical line marking approximate RNA position. Bracketed objects indicate promoters and gene products produced from pMU3 plasmid pictured below by a black line. (B) Increasing concentrations of transcription mutant RNA polymerase promotes trans-splicing. HeLa cells were transfected of static amounts mini-gene pSMN1 (lane a) or pSMN2 (lanes b-g) 1.25 microg , pM13 (lanes c-g) 0.75 microg, and increasing amounts of mutant Rpb1 RNA Polymerase subunit (pAT7-Rpb1MT) at 0.25, 0.75, 1.0 and 2.0 microg were harvested at 48 hrs. Reverse transcriptase PCR gel is displayed with GAPDH normalization control. (C) A genetically disabled SMN2 intron 7 deletion mini-gene displays enhances trans-splicing at reduced tsRNA plasmid concentrations. HeLa cells were cotransfected with pSMN1 (lane a), pSMN2 (lanes b,d), pSMN2DeltaIn7 (lanes e-h) 1.25 microg each and increasing concentrations of pM13 (lane d) 0.25 microg, (lanes e-h) 0.10, 0.25, 1.0 and 2.0 microg and the RNA harvested at 48 hrs. Reverse transcriptase PCR gel is displayed with GAPDH normalization control.
###end p 13
###begin title 14
###xml 47 56 47 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN trans</italic>
Identification of anti-sense RNA that enhances SMN trans-splicing
###end title 14
###begin p 15
###xml 106 115 106 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN trans</italic>
###xml 471 474 471 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 504 509 504 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 534 549 534 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003468.s001">Figure S1A, S1B</xref>
###xml 555 562 555 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Methods</xref>
###xml 637 641 637 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 685 694 685 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN trans</italic>
###xml 776 781 776 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 807 809 807 809 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 818 820 818 820 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 860 869 860 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003468-g002">Figure 2A</xref>
###xml 899 904 899 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 923 927 923 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 976 981 976 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 992 1005 992 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003468-g002">Figure 2B, 2C</xref>
###xml 1128 1133 1128 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
The previous experiments provided the impetus to identify a more tractable molecular mechanism to enhance SMN trans-splicing, such as antisense molecules. Antisense oligonucleotides (ASO) have proven to be an effective molecular means to modulate pre-mRNA splicing, primarily by inhibiting splice site selection. A panel of plasmids expressing short 18-22 nt ASOs complementary to the intron 7/exon 8 splice site were constructed and used to determine whether any of the SMN antisense RNAs could enhance trans-splicing. (Supplemental Figure S1A, S1B, see Methods) The ASO-expressing plasmids were co-transfected into HeLa cells with the SMN2 mini-gene and the pM13 which expresses the SMN trans-splicing RNA. A single lead candidate was identified that significantly elevated trans-splicing levels: ASO pIn711. ASO In711 overlaps the intron 7/exon 8 boundary (Figure 2A). Other ASO did not increase trans-splicing from the SMN2 mini-gene, or in some instances, even inhibited trans-splicing (Figure 2B, 2C). These results confirm the genetic experiments that ASO inhibition of a downstream splice site can significantly enhance trans-splicing efficiency in a mini-gene context.
###end p 15
###begin title 16
###xml 57 67 57 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2 trans</italic>
ASO mediated inhibition of downstream splicing increases SMN2 trans-splicing.
###end title 16
###begin p 17
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 184 186 176 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 292 297 280 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 542 545 528 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 597 602 583 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 682 686 668 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 697 701 683 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 788 789 766 767 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 904 909 878 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 937 939 911 913 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 1032 1035 1002 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 1052 1057 1022 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 1137 1141 1107 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 1152 1156 1122 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1244 1245 1206 1207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 1361 1366 1319 1324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1394 1396 1352 1354 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
(A) HeLa cells transfected with static amounts of pSMN1 (lane a), pSMN2 1.25 microg (lanes b-e) and pM13 (lane c-e) 0.75 microg are cotransfected with increasing concentrations of pIn711 (lane d,e) 0.25, 1.0 microg and RNA harvested at 48 hrs. Reverse transcriptase PCR gel is displayed with GAPDH normalization control. Graph represents independent triplicate repeats using a quantitative M13-Cy3 labeled primer and linear-range PCR amplification. Inset graph represents the average of triplicate repeats and error bars indicate +/-s.d. (B) SMN intron 6 ASO controls contribute to a reduction of trans-splicing. HeLa cells were triple transfected with static amounts of mini-gene pSMN1 (lane a) pSMN2 (lane b-g) 1.25 microg and pM13 (lane c-g) 0.75 microg with increasing amounts of pIn65 (lane e-g) 0.25, 0.75 and 1.0 microg and RNA harvested at 48 hrs. Reverse transcriptase PCR gel is displayed with GAPDH normalization control. pIn711 (lane c) 1.0 microg serves as a positive ASO-tsRNA control. (C) ASOs targeted internally to SMN intron 7 reduce trans-splicing. HeLa cells were triple transfected with static amounts of mini-gene pSMN1 (lane a) pSMN2 (lanes b-g) 1.25 microg and pM13 (lanes c-g) 1.0 microg with increasing amounts of pIn71 (lanes e-g) 0.25, 0.75 and 1.0 microg and RNA harvested at 48 hrs. Reverse transcriptase PCR gel is displayed with GAPDH normalization control. pIn711 (lane c) at 0.25 microg serves as a positive ASO-tsRNA control.
###end p 17
###begin p 18
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 98 101 98 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 123 125 123 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 181 186 181 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 212 215 212 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 248 252 248 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 257 261 257 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 371 376 371 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 385 388 385 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 457 459 457 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 461 470 461 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003468-g003">Figure 3A</xref>
###xml 484 489 484 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 698 702 698 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 949 951 949 951 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 1136 1138 1136 1138 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 1160 1169 1160 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003468-g003">Figure 3B</xref>
###xml 1343 1346 1343 1346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 1381 1386 1381 1386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 1458 1463 1458 1463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 590 597 <span type="species:ncbi:9606">patient</span>
###xml 670 677 <span type="species:ncbi:9606">patient</span>
To determine whether ASO-enhanced trans-splicing occurred in a more complex context of endogenous SMN gene expression, pIn711 and pM13 was co-transfected into HeLa cells to examine trans-splicing with endogenous SMN transcripts. HeLa cells express SMN1 and SMN2 genes and provide a robust level of target RNA. Consistent with the mini-gene analysis, endogenously derived trans-spliced SMN increased in a dose dependant manner with increasing amounts of pIn711 (Figure 3A). To examine trans-splicing in a more disease-specific context, similar co-transfections were performed in primary SMA patient fibroblasts, 3813 cells. The cells are derived from a severe Type I SMA patient and lack endogenous SMN1, and consequently contain very low levels of SMN-enriched nuclear structures called gems and express very low levels of full-length SMN protein. Extracts generated from 3813 cells co-transfected with pM13 and increasing concentrations of ASO pIn711 were analyzed for SMN levels using a SMN monoclonal antibody. Western blots demonstrated an ASO dose-dependent protein induction greater than control-treated 3813 cells as well as pIn711 alone treated cells (Figure 3B). SMN levels in the co-transfected cells were comparable to SMN levels detected in the unaffected control fibroblasts, 3814 cells. These results demonstrate that endogenous SMN transcripts can be re-directed by trans-splicing and that SMN levels can be significantly increased by the ASO/trans-splicing strategy in a relevant disease context.
###end p 18
###begin title 19
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
Endogenous enhancement of trans-splicing utilizing combined delivery of ASO and tsRNA.
###end title 19
###begin p 20
###xml 26 28 26 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 55 64 55 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN trans</italic>
###xml 174 176 170 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 291 296 283 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 324 325 316 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 403 405 391 393 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 578 580 562 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 677 679 657 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 467 474 <span type="species:ncbi:9606">patient</span>
(A) Dose dependant ASO In711 enhancement of endogenous SMN trans-splicing. HeLas were cotransfected with pM13 (lanes a-e) 1.0 microg and increasing concentrations of ASO pIn711 (lanes c-e) 0.25, 2.0 and 5.0 microg and RNA harvested at 48 hrs. Reverse transcriptase PCR gel is displayed with GAPDH normalization control. pIn65 (lane a) 2.0 microg serves as a negative control. (B) Dose dependant ASO pIn711 enhancement of pM13 mediated SMN protein induction. 3813 SMA patient fibroblasts were co-transfected with pM13 (lanes d-f) 0.75 microg and increasing concentrations of pIn711 (lanes d-f) 0.50, 1.0 and 2.0 microg and cells harvested at 24 hrs and run on 10% SDS-PAGE. pIn711 alone (lane c) 2.75 microg and ssDNA (lanes a, b) 2.75 microg serve as negative controls. beta-actin antibody panel serves as a normalization control.
###end p 20
###begin title 21
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
Development of a single vector for anti-sense and trans-splicing RNA delivery
###end title 21
###begin p 22
###xml 103 108 103 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 223 225 223 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 244 253 244 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN trans</italic>
###xml 285 287 285 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 415 418 415 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 477 486 477 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003468-g001">Figure 1A</xref>
###xml 572 575 572 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M13</sup>
###xml 604 606 604 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 725 734 725 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN trans</italic>
###xml 773 776 773 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 790 793 790 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 922 924 922 924 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 934 936 934 936 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 939 948 939 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003468-g004">Figure 4A</xref>
###xml 1011 1014 1011 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 1130 1135 1130 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 1210 1219 1210 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003468-g004">Figure 4B</xref>
In envisioning a therapeutic application, a dual vector strategy is likely to reduce the efficiency of trans-splicing. Therefore, a single vector was constructed that was combined the molecular constituents of pM13 and pIn711 by subcloning the SMN trans-splicing cassette into the pIn711 plasmid backbone. This single vector platform allows for the production of two individual RNAs that target distinct aspects of SMN pre-mRNA, leading to enhanced full-length SMN expression (Figure 1A). The ASO-tsRNA plasmid (pMU3) produces three gene products, the Pol II-derived tsRNAM13, the Pol III-derived ASO In711, and the Pol II-derived eGFP. Consistent with the co-transfections, the single pMU3 vector resulted in high levels of SMN trans-splicing between endogenous HeLa cell SMN transcripts. SMN levels were elevated nearly three fold compared to the pM13 vector and a pMU3 vector that lacks the promoter that drives the In711 RNA (pMU3KO) (Figure 4A). The pMU3 vector was also capable of re-directing endogenous SMN pre-mRNA splicing in primary SMA fibroblasts, resulting in approximately a three-fold increase over pM13 levels of trans-splicing and a comparable increase in steady state levels of SMN protein (Figure 4B).
###end p 22
###begin title 23
###xml 76 85 76 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN trans</italic>
Development of a single plasmid ASO-tsRNA system (pMU3) enhances endogenous SMN trans-splicing.
###end title 23
###begin p 24
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 127 129 123 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 271 276 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 447 452 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 582 584 566 568 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 729 731 697 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 834 839 798 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 472 479 <span type="species:ncbi:9606">patient</span>
(A) pMU3 enhances trans-splicing capabilities in a single vector. HeLas were transfected with pM13 (lane a) 0.75 microg or pMU3KO (lane b) 0.75 microg or pMU3 (lanes c,d) 0.75 and 1.0 microg and RNA harvested 48 hrs later. Reverse transcriptase PCR gel is displayed with GAPDH normalization control. Inset graph represents triplicate repeats. (B) In SMA relevant contexts the single plasmid ASO-tsRNA system (pMU3) produces the greatest amount of trans-splicing. 3813 SMA patient fibroblasts were transfected with pM13 for basal level (lane c) 0.75 microg or cotransfected with pIn711 0.50 microg and pM13 0.50 microg together (lane d) or pMU3 (lane e) 0.75 microg and RNA harvested at 48 hrs. ssDNA (lane a) 0.75 microg and pIn711 alone (lane b) 2.0 microg serve as negative controls. Reverse transcriptase PCR gel is displayed with GAPDH normalization control. Inset graph represents the average of triplicate repeats and error bars indicate +/-s.d.
###end p 24
###begin title 25
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trans</italic>
Trans-splicing restores SMN-dependent major and minor snRNP assembly
###end title 25
###begin p 26
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 134 142 134 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 231 235 231 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Pellizzoni1">[22]</xref>
###xml 419 421 419 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 570 575 570 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 756 769 756 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003468-g005">Figure 5A, 5B</xref>
###xml 1019 1023 1019 1023 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATAC</sup>
###xml 1029 1033 1029 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Gabanella1">[23]</xref>
###xml 1095 1100 1095 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 1141 1149 1141 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1192 1196 1192 1196 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATAC</sup>
###xml 1203 1212 1203 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003468-g005">Figure 5C</xref>
###xml 1344 1348 1344 1348 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATAC</sup>
To monitor the functionality of the SMN protein produced downstream of the trans-splicing event, SMN protein function was measured by in vitro snRNP assembly assays. The best described activity for SMN is a role in UsnRNP assembly [22]. Using SMN-deficient extracts from 3813 cells that normally support very low levels of snRNP assembly, extracts were generated from cells transfected with salmon sperm DNA, pM13, pIn711, or pMU3. Extracts derived from pMU3 transfected cells exhibited a two to four-fold increase compared to untreated extracts, demonstrating that the trans-splicing event not only generates higher levels of protein, but that SMN protein produced through this pathway is functional in a critical cellular process ascribed to native SMN (Figure 5A, 5B). These assays examined the ability of SMN to form snRNP on a U1 snRNA, which is part of the major spliceosomal pathway, however, SMN has also recently been shown to be involved in snRNP biogenesis of the minor spliceosome pathway, including the U11ATACsnRNA [23]. To determine if this critical function was also restored in trans-splicing treated cell extracts, similar in vitro assembly assays were performed using a U11ATACsnRNA (Figure 5C). Consistent with the U1 results, pMU3 treated extracts were able to significantly elevate functional SMN levels as measured by U11ATACsnRNP assembly. Collectively, these results demonstrate that the pMU3 system results in high levels of functional SMN protein that is capable of performing UsnRNP biogenesis of the major and minor spliceosomal pathways to levels comparable to unaffected cells.
###end p 26
###begin title 27
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 86 93 <span type="species:ncbi:9606">patient</span>
Single vector dosages with enhanced trans-splicing produces functional SMN protein in patient fibroblasts.
###end title 27
###begin p 28
###xml 216 218 212 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 393 395 373 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 653 661 624 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 907 909 866 868 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 1110 1118 1063 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1385 1389 1330 1334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATAC</sup>
###xml 106 113 <span type="species:ncbi:9606">patient</span>
###xml 701 708 <span type="species:ncbi:9606">patient</span>
###xml 1179 1186 <span type="species:ncbi:9606">patient</span>
(A) The pMU3 single plasmid ASO-tsRNA system produces the greatest amount SMN protein induction. 3813 SMA patient fibroblasts were transfected with pM13 for basal level (lane d) 0.75 microg or cotransfected with pIn711 0.50 microg and pM13 0.50 microg together (lane e) or pMU3 (lane f) 0.75 microg cells were harvested at 24 hrs and run on 10% SDS-PAGE. ssDNA (lanes a,b) 0.75 microg and pIn711 alone (lane c) 2.0 microg serve as negative controls. beta-actin antibody panel serves as a normalization control. Inset graph represents the average of triplicate repeats and error bars indicate +/-s.d. (B) The pMU3 system restores SMA primary fibroblasts in vitro capacity to assemble U1snRNP. 3813 SMA patient fibroblasts were transfected with pM13 (lane e) 0.75 microg for basal level or pMU3 (lane d) 0.75 microg cells were harvested at 24 hrs and S100 extract prepared. ssDNA (lane b) 0.75 microg and pIn711 alone (lane c) 2.0 microg serve as negative controls. Inset graph represents the average of triplicate repeats and error bars indicate +/-s.d. (C) The pMU3 system restores the SMA primary fibroblasts in vitro capacity for minor spliceosome U11 snRNP assembly. 3813 SMA patient fibroblasts were transfected with pMU3 (lane d) 0.75 microg or ssDNA (lanes b,c) 0.75 microg. ssDNA. 3813 and 3814 (lanes b and c) serve as negative and positive controls respectively for U1 and U11ATAC assembly. (*) indicates band of interest.
###end p 28
###begin p 29
###xml 518 521 518 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GFP</italic>
###xml 774 787 774 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003468-g006">Figure 6A, 6B</xref>
###xml 1006 1015 1006 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003468-g006">Figure 6A</xref>
###xml 1132 1136 1132 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1144 1149 1144 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 1196 1204 1196 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
A frequently examined biomarker for SMN is a sub-cellular structure called gems. Gems are nuclear foci enriched in SMN and several SMA binding partners. Gems have proven a valuable tool to monitor the efficiency of SMN induction from a variety of therapeutic molecules, ranging from drugs to viral vectors. To determine whether pMU3 increased SMN gems, fibroblasts transfected with pMU3 plus a panel of negative controls were examined by indirect immunofluorescence. Transfected cells were readily detected due to the GFP expression from the plasmid backbone. In GFP-positive 3813 cells, pMU3 treated gems levels were significantly increased, resulting in nearly 60 gems per 100 nuclei and with approximately 30-40% of transfected cells expressing at least one to two gems (Figure 6A, 6B). Negative controls for fibroblast transfection and cellular reaction included plasmids lacking a viable tsRNA promoter sequence and empty pMU2 plasmid demonstrated therapeutically irrelevant increases in gem numbers (Figure 6A). Therefore we concluded that the ASO-tsRNA technology achieves the greatest biological impact relative to previous SMN2 exon 7 trans-splicing theories in these well-characterized in vitro assays.
###end p 29
###begin title 30
pMU3 transfected SMA primary fibroblasts display increased gem numbers.
###end title 30
###begin p 31
###xml 13 20 <span type="species:ncbi:9606">patient</span>
(A) 3813 SMA patient fibroblasts were transfected with pMU3 0.75 microg or ssDNA 0.75 microg and fixed at 24 hrs. Immunohistochemistry was performed using alphaSMN antibody 4B7 and visualized with Texas Red 594, nuclei with DAPI. White arrows indicate examples of gem structures in the red anti-SMN panel. (B) Graphical summary of averaged SMN gem counts in 300 GFP positive 3813 fibroblasts. Error bars represent +/-SD. Statistical significance relating pM13 to pMU3 determined by values of p<0.05.
###end p 31
###begin title 32
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
pMU3-mediated trans-splicing increases SMN protein in SMA mice
###end title 32
###begin p 33
###xml 88 95 88 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 185 194 185 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN&#916;7</italic>
###xml 194 198 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Le1">[24]</xref>
###xml 249 253 245 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 273 282 269 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN&#916;7</italic>
###xml 387 389 379 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sup>
###xml 670 675 662 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 734 743 726 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans-SMN</italic>
###xml 777 786 769 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003468-g007">Figure 7A</xref>
###xml 828 831 820 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GFP</italic>
###xml 949 958 941 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003468-g007">Figure 7A</xref>
###xml 1343 1352 1335 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003468-g007">Figure 7B</xref>
###xml 1470 1483 1462 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003468-g007">Figure 7C, 7D</xref>
###xml 1546 1553 1538 1545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1699 1708 1691 1700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN trans</italic>
###xml 1758 1767 1750 1759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN trans</italic>
###xml 1777 1784 1769 1776 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 150 155 <span type="species:ncbi:10090">mouse</span>
###xml 208 214 <span type="species:ncbi:10090">murine</span>
###xml 243 248 <span type="species:ncbi:9606">human</span>
###xml 267 272 <span type="species:ncbi:9606">human</span>
###xml 302 306 <span type="species:ncbi:10090">mice</span>
###xml 931 935 <span type="species:ncbi:10090">mice</span>
###xml 1249 1253 <span type="species:ncbi:10090">mice</span>
To determine whether the cell-based analysis of pMU3 translated into comparable results in vivo, SMN proteins were examined in a previously described mouse model of SMA, referred to as SMNDelta7[24]. The SMA murine model expresses the genomic human SMN2 gene and the human SMNDelta7 cDNA. SMA neonatal mice were injected into both cerebral lateral ventricles with pMU3 or pM13 at 1.14x1012 plasmid copies using 25 kDa linear PEI and glucose. Negative control injections contained glucose, saline, and 25 kDa linear PEI to control for procedure and cytotoxicity. After 24 hours the spinal cord was dissected and used to generate total RNA and protein extracts. Utilizing trans-splicing specific RT-PCR primers we identified a positive trans-SMN mRNA product in the spinal cord (Figure 7A). Northern and southern blotting using a GFP-specific probe demonstrated that similar levels of plasmid were present in each of the treated SMA mice (lower panel Figure 7A, and data not shown, respectively). Western blots of disassociated whole spinal cord extracts from five individual pMU3-treated SMA pups were examined and shown to contain significantly elevated levels of SMN protein. pMU3-induced levels of SMN were significantly higher than untreated SMA mice and were comparable to SMN levels detected in homogenates from unaffected heterozygotes (Figure 7B). In contrast, the parental vector that lacked the ASO, pM13, did not result in significant levels of SMN induction (Figure 7C, 7D). Similarly, the ASO-alone vector failed to induce SMN levels in vivo (data not shown). Taken together, these results demonstrate that the pMU3 vector strategy that encodes two separate RNAs significantly increases SMN trans-splicing and provides the first demonstration of SMN trans-splicing in vivo.
###end p 33
###begin title 34
###xml 67 71 <span type="species:ncbi:10090">mice</span>
Intracerebroventricular 25 kDa PEI pMU3 transfections in SMA model mice increases SMN protein in the spinal cord.
###end title 34
###begin p 35
###xml 19 22 19 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 29 32 29 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 39 49 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;7 SMN</italic>
###xml 97 100 93 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 107 110 103 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 117 127 113 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;7 SMN</italic>
###xml 215 217 203 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sup>
###xml 432 439 420 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 459 464 447 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 933 936 918 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 943 946 928 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 953 963 938 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;7 SMN</italic>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
###xml 301 305 <span type="species:ncbi:10090">mice</span>
###xml 697 702 <span type="species:ncbi:10090">mouse</span>
###xml 871 875 <span type="species:ncbi:10090">mice</span>
###xml 995 999 <span type="species:ncbi:10090">mice</span>
###xml 1367 1371 <span type="species:ncbi:10090">mice</span>
(A) Heterozygous (mSMN +/+, hSMN +/+, hDelta7 SMN cDNA +/+) (lane a) or homozygous (lanes b-g) (mSMN -/-, hSMN +/+, hDelta7 SMN cDNA +/+) neonatal mice (PND 0-1) were injected with pMU3 plasmid at 10 microg (1.14x1012 plasmid copies) with 25 kDa PEI over two ventricles (lanes c-g). Mock transfection mice are shown in lane a and b. Whole spinal cord homogenates were prepared for protein or RNA extraction 24 hours post injection. In vivo RT-PCR results for trans-spliced SMN are shown in the upper panel. Lower panel depicts controls for vector expression via northern blot of mock or treatment group spinal cord RNA loaded on nitrocellouse and developed with a radio-labeled GFP probe. (B) SMA mouse spinal cord protein was resolved on 10% SDS-PAGE. beta-actin antibody panel serves as a normalization control. (C) Intra-ventricular transfections of pM13 in SMA model mice do not alter SMN levels in the spinal cord. Homozygous (mSMN -/-, hSMN +/+, hDelta7 SMN cDNA +/+) (lanes b,c) neonatal mice (PND 0-1) were injected with 10 microg of plasmid with 25 kDa PEI over both ventricles. Whole spinal cord homogenates were prepared for protein and resolved on 10% SDS-PAGE. beta-actin antibody panel serves as a normalization control. Mock treatment is depicted in lane a. (D) Graphical summary of injection outcomes relative to SMN protein induction western blot in mice. Error bars represent +/-s.d. HET, KO, pM13 (n = 4). pMU3 (n = 5).
###end p 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 67 72 67 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 317 321 317 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Coady1">[15]</xref>
###xml 362 369 362 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 431 436 431 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 542 549 542 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
This is the first demonstration of a technique designed to enhance trans-splicing efficiency by blocking downstream splice site selection. While the initial trans-splicing RNA alone showed considerable activity in cell-based models of SMA in terms of significantly increasing SMN levels and increasing snRNP activity [15], these results did not translate to the in vivo context. Our research highlights a key finding that low dose trans-splicing is enhanced by the co-expression of the ASO and resulted in detectable levels of SMN expression in vivo.
###end p 37
###begin p 38
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 159 162 159 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Wood1">[7]</xref>
###xml 247 250 247 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 431 440 431 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN trans</italic>
###xml 589 594 589 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
As a therapeutic approach, trans-splicing offers the advantage over gene replacement in that expression is intrinsically controlled by the endogenous promoter [7]. Consequently, temporal and spatial constraints on gene expression are retained. As SMN expression has previously been shown to be significantly down-regulated from embryogenesis to adulthood, this additional restraint may prove beneficial for long-term exposure to a SMN trans-splicing vector. Avenues of research directed to the reduction of tsRNA vector dosage would consequently inhibit the negative effects of off-target trans-splicing over greater amounts of time.
###end p 38
###begin p 39
###xml 109 114 109 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 273 281 273 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2 cis</italic>
###xml 295 300 295 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 364 369 364 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 386 389 386 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 500 505 500 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
The genetic context of SMA represents an intriguing target for a number of therapeutic strategies, including trans-splicing. In the SMN2 gene, the intrinsic quality of the exon 7 splice acceptor site is reduced due to the C/T transition. Therefore, the competition between SMN2 cis-splicing and trans-splicing is likely reduced, providing a potential advantage to trans-splicing in the SMN context compared to other alternatively regulated exons that retain fully functional splice sites. We propose trans-splicing is further enhanced relative to cis-splicing with the introduction of an inhibitory ASO. Since the tsRNA annealing domain hybridizes over the target exon, it is logical that this may promote exon 7 skipping. Therefore, the addition of the anti-sense likely blocks this escape pathway and further promotes trans-splicing. Unlike many ASOs that modify splicing, the ASOs used in this context are native RNA structures, not oligonucleotides with modified backbones. Therefore, the affects may be difficult to observe at steady-state levels when used as an ASO alone. However, given that this sequence overlaps the intron 7/exon 8 boundary, it was not surprising that the ASO recapitulated the increase in trans-splicing observed with the slow polymerase and intron 7-deleted construct.
###end p 39
###begin p 40
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 177 180 177 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 275 277 275 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 287 290 287 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EX4</sup>
###xml 324 327 324 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 391 396 391 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 421 430 421 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003468.s002">Figure S2</xref>
###xml 805 810 805 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 836 841 836 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
In general, the field of trans-splicing therapeutics can benefit from the discovery of combined ASO-tiling and tsRNAs. ASO-tiling increases the potential of tsRNA by modulating cis-splicing signals within the target transcript. Additionally, in a novel application of ASO-In411 and tsRNAEX4 co-delivery targeting a upstream SMN intron 3 exon 4 splicing context produced enhancement of basal trans-splicing. (Supplemental Figure S2) Studies here demonstrate the limitations of dual vector delivery in difficult fibroblast transfection conditions. Co-transfection dynamics hinder the potential of ASO/tsRNA pre-mRNA redirection and can be circumvented by sub-cloning of the single vector pMU3. The combination of ASO-tsRNA mechanism and a novel single vector platform produces a potent enhancement of basal trans-splicing. In the case of trans-splicing RNAs designs such as, 5' or 3' versions would require examination of beneficial upstream and downstream sequences to tile with ASO RNA.
###end p 40
###begin p 41
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 267 271 267 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 460 465 460 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 493 497 493 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 510 513 510 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 626 633 626 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 657 662 657 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 593 598 <span type="species:ncbi:10090">mouse</span>
The in vivo results demonstrate ASO-tsRNA represents a tractable therapeutic yet highlight the transient nature of plasmid transfections. The use of AAV vectors for the delivery of gene therapies would provide a substantial longevity to ASO-tsRNA expression and thus SMN2 redirection. Future studies could examine the role of expression of the virus vectors and the SMA CNS. We conclude the combined effects of ASO-tsRNAs in a novel expression vector enhanced trans-splicing in the context of SMN2 alternative cis-splicing. Applications of this biotechnology on a well characterized SMA model mouse demonstrate the promise of in vivo restoration of SMN via trans-splicing RNAs.
###end p 41
###begin title 42
Materials and Methods
###end title 42
###begin title 43
Plasmids and cloning
###end title 43
###begin p 44
###xml 14 17 14 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M13</sup>
###xml 67 71 67 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Coady1">[15]</xref>
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 86 90 86 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 104 108 104 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 111 115 111 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 148 152 148 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Lorson1">[12]</xref>
###xml 165 169 165 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 169 177 169 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;In7</sup>
###xml 169 177 169 173 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>&#916;In7</sup></bold>
###xml 320 360 316 356 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- TCCTTAAATTAAGGAGAAATGCTGGCATAGAGC-3&#8242;</named-content>
###xml 478 482 474 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rpb1</italic>
###xml 536 540 532 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-delaMata1">[21]</xref>
###xml 664 668 660 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Baughan1">[14]</xref>
###xml 721 722 717 718 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">X</sup>
###xml 783 784 779 780 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">X</sup>
###xml 859 862 855 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 872 873 868 869 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">[</bold>
###xml 873 876 869 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 873 876 869 872 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN</italic></bold>
###xml 876 886 872 882 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> EXON 6]5&#8242;</bold>
###xml 892 893 888 889 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 894 925 890 921 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-uucugaucauauuuuguugaauaaa-3&#8242;</named-content>
###xml 931 932 927 928 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 933 960 929 956 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;uuuguugaauaaaauaaguaaaaug</named-content>
###xml 966 967 962 963 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 968 996 964 992 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;auaaguaaaaugucuugugaaacaaa</named-content>
###xml 1002 1003 998 999 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1004 1032 1000 1028 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;gucuugugaaacaaaaugcuuuuuaa</named-content>
###xml 1038 1039 1034 1035 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1040 1067 1036 1063 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;aaugcuuuuuaacauccauauaaag</named-content>
###xml 1070 1073 1066 1069 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3&#8242;[</bold>
###xml 1073 1076 1069 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 1073 1076 1069 1072 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN</italic></bold>
###xml 1076 1085 1072 1081 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> EXON7]5&#8242;</bold>
###xml 1091 1092 1087 1088 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 1093 1122 1089 1118 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;auaugggaauaaccuaggcauacugca</named-content>
###xml 1128 1129 1124 1125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1130 1158 1126 1154 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;cuaggcauacugcacuguacacucug</named-content>
###xml 1164 1165 1160 1161 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1166 1194 1162 1190 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;cacuguacacucugacauaugaagug</named-content>
###xml 1200 1201 1196 1197 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1202 1226 1198 1222 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;acauaugaagugcucuagucaa</named-content>
###xml 1232 1233 1228 1229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1234 1263 1230 1259 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;gcucuagucaaguuuaacuggugucca</named-content>
###xml 1269 1270 1265 1266 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1271 1298 1267 1294 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;uuuaacugguguccacagaggacau</named-content>
###xml 1304 1305 1300 1301 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 1306 1331 1302 1327 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;acagaggacaugguuuaacugga</named-content>
###xml 1337 1338 1333 1334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 1339 1365 1335 1361 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;gguuuaacuggaauucgucaagcc</named-content>
###xml 1371 1372 1367 1368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sup>
###xml 1373 1404 1369 1400 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;ggaauucgucaagccucugguucuaauuu</named-content>
###xml 1410 1412 1406 1408 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sup>
###xml 1413 1439 1409 1435 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;ugguucuaauuucucauuugcagG</named-content>
###xml 1445 1447 1441 1443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 1448 1476 1444 1472 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;ucucauuugcagGAAAUGCUGGCAUA</named-content>
###xml 1479 1482 1475 1478 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3&#8242;[</bold>
###xml 1482 1485 1478 1481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 1482 1485 1478 1481 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN</italic></bold>
###xml 1485 1492 1481 1488 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> EXON8]</bold>
###xml 1496 1499 1492 1495 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">712</sup>
###xml 1500 1527 1496 1523 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;AAUGCUGGCAUAGAGCAGCACUAAA</named-content>
###xml 1533 1535 1529 1531 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sup>
###xml 1536 1562 1532 1558 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;AUGACACCACUAAAGAAACGAUCA</named-content>
###xml 1568 1570 1564 1566 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 1571 1598 1567 1594 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;AAGAAACGAUCAGACAGAUCUGGAA</named-content>
###xml 1686 1688 1682 1684 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 1719 1722 1715 1718 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pfx</italic>
###xml 1920 1922 1916 1918 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 1951 1953 1947 1949 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 2092 2095 2088 2091 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EX4</sup>
###xml 2180 2226 2176 2222 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- ATCAAGCTTGAGCTCAAAAAGAAAAAATATGCAGGTTTT-3&#8242;</named-content>
###xml 2241 2281 2237 2277 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ATCACCGCGGTTCAATTTCTGGAAGCAGAGACTA-3&#8242;</named-content>
###xml 2427 2472 2423 2468 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TCAGATATCCTGCAGAGAATGAAAATGAAAGCCAAGTTT-3&#8242;</named-content>
###xml 2487 2555 2483 2551 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- CATTCTCGAGGGGCCCGTCATAGCTGTTTCCTGCGACTCCTTAATTTAAGGAATGTGAGCA-3&#8242;</named-content>
###xml 2610 2612 2606 2608 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 2681 2683 2677 2679 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 2689 2729 2685 2725 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AGCTGTACAAGTAAAGCGGCCGCGACTCTAGATC-3&#8242;</named-content>
###xml 2743 2745 2739 2741 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 2751 2818 2747 2814 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- GTAACGCGTAAAAAATTCCTTATAGCCAGGTCTAAAATGGATCCGAAGACCACAAACAAG-3&#8242;</named-content>
###xml 2851 2853 2847 2849 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 3109 3114 3095 3100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 3161 3168 3147 3154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 3214 3217 3200 3203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 3169 3175 <span type="species:ncbi:10090">murine</span>
The pMU2-tsRNAM13 clone reported previously is now written as pM13 [15]. The SMN1 and SMN2 mini-genes (pSMN1, pSMN2) have been previously described [12]. Mini-gene pSMN2DeltaIn7 was created by using overlapping PCR primers which anneal the 5' splice donor of exon 7 to the 3' splice acceptor of exon 8. SMN In7 DEL FWD (5'- TCCTTAAATTAAGGAGAAATGCTGGCATAGAGC-3') This PCR product was then gel purified and cloned into the pCI minigene using 5'-NheI and NotI-3'. The plasmid pAT7-Rpb1- (N792D) (R749H) expresses the mutant RNA polymerase [21]. The Antisense Oligonucleotides (ASO) was cloned into the previously reported pMU2 plasmid context driven by a U6 promoter [14]. Sequences were chosen with intron 6 dentoted as In6X (with X indicated the sequential number) and intron 7 as In7X. Listed below are the binding domains for the ASO as read 5' to 3' in the SMN pre-mRNA [SMN EXON 6]5'- (In61-5'-uucugaucauauuuuguugaauaaa-3') (In62-5'uuuguugaauaaaauaaguaaaaug) (In63-5'auaaguaaaaugucuugugaaacaaa) (In64-5'gucuugugaaacaaaaugcuuuuuaa) (In65-5'aaugcuuuuuaacauccauauaaag) -3'[SMN EXON7]5'- (In71-5'auaugggaauaaccuaggcauacugca) (In72-5'cuaggcauacugcacuguacacucug) (In73-5'cacuguacacucugacauaugaagug) (In74-5'acauaugaagugcucuagucaa) (In75-5'gcucuagucaaguuuaacuggugucca) (In76-5'uuuaacugguguccacagaggacau) (In77-5'acagaggacaugguuuaacugga) (In78-5'gguuuaacuggaauucgucaagcc) (In79-5'ggaauucgucaagccucugguucuaauuu) (In710-5'ugguucuaauuucucauuugcagG) (In711-5'ucucauuugcagGAAAUGCUGGCAUA) -3'[SMN EXON8] (In712-5'AAUGCUGGCAUAGAGCAGCACUAAA) (In713-5'AUGACACCACUAAAGAAACGAUCA) (In714-5'AAGAAACGAUCAGACAGAUCUGGAA) The pMU3 construct produces three gene products, tsRNA, eGFP protein and ASOs. ASO-In711 was subcloned by PCR Platinum Pfx DNA Polymerase (Invitrogen) amplification according to the manufacture instructions of the U6 promoter and the antisense RNA and cloned by flanking restriction sites 5'-BlpI and AsiSI-3'(NEB). pMU3KO is a substitution of the In711 anti-sense RNA with a random sequence of RNA created by overlapping PCR and cloned using the same restrictions sites above. The pMU2-tsRNAEX4 intron 3 binding domain was amplified from HeLa genomic DNA using primers (Int3 Rev 5'- ATCAAGCTTGAGCTCAAAAAGAAAAAATATGCAGGTTTT-3') and (Int3 Fw 5'-ATCACCGCGGTTCAATTTCTGGAAGCAGAGACTA-3') and cloned into HindIII-SacII of pcDNA3/PTM2 replacing Int6 binding domain. Exons 4-7 were amplified from SMN1 cDNA clone using primers (Ex4 Fw 5'-TCAGATATCCTGCAGAGAATGAAAATGAAAGCCAAGTTT-3') and (Ex7 Rev 5'- CATTCTCGAGGGGCCCGTCATAGCTGTTTCCTGCGACTCCTTAATTTAAGGAATGTGAGCA-3') and cloned into EcoRV and XhoI sites of pMU2. The In411 antisense fragment was amplified from pMU3 construct using BsrGI In711 (Fwd 5'-AGCTGTACAAGTAAAGCGGCCGCGACTCTAGATC-3') and MluI In411 (Rev 5'- GTAACGCGTAAAAAATTCCTTATAGCCAGGTCTAAAATGGATCCGAAGACCACAAACAAG-3') and was cloned to make pMU2-In411, the antisense fragment into the BsrGI-MluI sites of pMU2 vector. Ligations were carried out using 10-15 units of T4 DNA Ligase (NEB) at 15degreesC for 24 hours and transformed in Subcloning Max Efficency DH5alpha. (Invitrogen) Sequencing of gel purified trans-splicing SMN M13 positive cDNAs produced from in vivo murine RT-PCR was performed using 1.5 ng of hSMN Exon 6 Forward primer and on a ABI 3730 DNA Analyzer and Applied Biosystems Big Dye Terminator system and read by Chromat Freeware.
###end p 44
###begin title 45
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro Transfections
###end title 45
###begin p 46
###xml 747 748 737 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 924 925 914 915 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</underline>
###xml 931 932 921 922 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</underline>
###xml 937 940 927 930 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DNA</underline>
###xml 1198 1199 1179 1180 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1256 1257 1237 1238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1298 1299 1279 1280 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1422 1423 1403 1404 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1426 1427 1407 1408 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1436 1437 1417 1418 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1439 1440 1420 1421 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 836 842 <span type="species:ncbi:9913">bovine</span>
###xml 1058 1065 <span type="species:ncbi:9606">patient</span>
The transfections were performed using linear PEI (Polysciences, Inc.) to pH 8.3 with 20 microL adjustments of HCl or NaOH. Stock linear 250 kDa PEI for HeLa in vitro transfections were snap frozen in liquid nitrogen and thawed 5 times at 37degreesC. Triple transfections in HeLas required "mean-low molecular weight PEI," stock PEI was sonicated on ice at 30% total power for 30 seconds three times. Plasmids were transfected into HeLa or HEK293 cells (Coriell Cell Repositories) grown to 80% confluence before transfection. Plasmids were diluted in a 150 mM NaCl solution before adding filtered linear 7.5 mM 250 kDa PEI. Cells were incubated with plasmid overnight and replenished with fresh Dulbecco's Modified Eagle Media High Glucose 1x DMEM+ (D-glucose 4.5 g/L, +L-glutamine, 1% penicillin/streptomycin 10 000 units/mL, 3% fetal bovine serum-endotoxin free) and harvested 48 hours post-transfection. Controls include salmon sperm DNA (ssDNA) (Invitrogen) and normalized across co-transfection samples to greatest treatment plasmid DNA micrograms. SMA patient fibroblasts (GM3813) were transfected with Lipofectaminetrade mark2000 with LiCl (5M) centrifuge purified plasmid in serum free DMEM- for 4 hours then washed via media and replaced with DMEM+ for 2 hours. Finally complete media DMEM+ was added back for the remaining incubation. Cells were harvested 24 hours later in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4) pH 7.5-8.0. ASO-tsRNA co-transfections used ssDNA to control for total volume of DNA. Post-transfection harvested cells were counted on a hemocytometer and use Trypan blue dye exclusion to determine viable cell counts per microliter.
###end p 46
###begin title 47
RT-PCR
###end title 47
###begin p 48
###xml 296 300 296 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Baughan1">[14]</xref>
###xml 306 311 306 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 371 398 371 398 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GTCATAGCTGTTTCCTGCGAC-3&#8242;</named-content>
###xml 515 519 515 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Lorson1">[12]</xref>
###xml 601 605 601 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Lorson1">[12]</xref>
###xml 665 668 665 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 686 713 686 713 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CCCCCACCACCTCCCATATGT-3&#8242;</named-content>
###xml 719 722 719 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 739 766 739 766 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AGTGGTGTCATTTAGTGCTGC-3&#8242;</named-content>
###xml 794 797 794 797 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EX4</sup>
###xml 807 812 807 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 858 862 858 862 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+126</sup>
###xml 868 901 868 901 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GAGAGGAGCAAAATCTGTCCGATCTAC-3&#8242;</named-content>
###xml 931 936 931 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 969 972 969 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 1149 1154 1149 1154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 1350 1359 1350 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans-SMN</italic>
###xml 1399 1408 1399 1408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans-SMN</italic>
###xml 1437 1442 1437 1442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 1443 1452 1443 1452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN:GAPDH</italic>
###xml 1515 1520 1515 1520 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 1549 1558 1549 1558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN trans</italic>
###xml 1636 1641 1636 1641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
48 hours post transfection or transduction, total RNA was harvested from cells using TRIzol Reagent (Invitrogen) according to the manufacturer's instruction. Total RNA concentration determined via Nano-drop OD260 and normalized before cDNA synthesis. RT-PCR was performed as previously described [14]. The trans-splicing product was amplified using a reverse primer M13 (5'-GTCATAGCTGTTTCCTGCGAC-3') 5' Cy3 labeled (564 nm emission max) (Intergrated DNA Technologies, Inc.) and a mini-gene specific primer, pCI-Fwd [12]. The SMN1 and 2 mini-gene transcripts were amplified using pCI-Fwd#1 and pCI-Rev [12]. The primers used in endogenous PCR amplifications were an SMN Exon 6 -Forward (5'-CCCCCACCACCTCCCATATGT-3') and SMN Exon 8-Reverse (5'-AGTGGTGTCATTTAGTGCTGC-3'). The endogenous pMU2-tsRNAEX4 mediated trans-SMN product was amplified using primer Exon 3+126 (Fwd 5'-GAGAGGAGCAAAATCTGTCCGATCTAC-3') and M13 Rev. The endogenous trans-spliced product is amplified by SMN Exon 6 (+7) Forward and M13 Reverse. Negative RT polymerase controls were included in protocol but omitted from final figures. Semi-quantitative determinations via Cy3 labeled trans-splicing products were imaged using laser Fuji-Imager FLA5000 at 550 nm excitation range. RT-PCRs were repeated in triplicate to confirm 2-tail t-test statistical significance of the increase in trans-SMN mRNA. To normalize within experiments, trans-SMN induction is determined as (trans-SMN:GAPDH) and between experiments levels were normalized to basal pM13 trans-splicing values (set to 1). SMN trans-splicing was measured using fold change over pM13 set to 1 as expressions of trans-splicing efficiency.
###end p 48
###begin title 49
Immunofluorescence microscopy
###end title 49
###begin p 50
###xml 290 294 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Baughan1">[14]</xref>
###xml 647 651 647 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Wolstencroft1">[25]</xref>
###xml 4 11 <span type="species:ncbi:9606">patient</span>
###xml 409 414 <span type="species:ncbi:10090">mouse</span>
###xml 470 474 <span type="species:ncbi:9925">goat</span>
###xml 480 485 <span type="species:ncbi:10090">mouse</span>
SMA patient fibroblasts (Coriell Cell Repositories, 3813 cells) harvested at sub-confluent levels were plated for transfections on UV irradiated glass coverslips. Prior to harvest, samples were washed twice in PBS pH 7.5. Fixation of cells was performed using cold acetone/methanol (50:50) [14]. 1% BSA was used as a blocking medium for 1 hour then the samples were washed in PBS pH 7.0. Primary antibody 4B7 mouse anti-SMN was diluted 1:500 in PBS. Secondary antibody (goat anti-mouse Texas Red-594: Jackson Immuno-Research Laboratories) were used according to manufacturer's instructions. Cells were washed with PBS and nuclei stained with DAPI [25]. Microscope images were captured on Nikon Eclipse E1000 using Meta-Morph software. Control exposures determining levels of background for the secondary in the absence of primary antibody set basal limits for SMN detection. These controls are performed during each experimental round to control for intra-assay perturbations.
###end p 50
###begin title 51
Western blot
###end title 51
###begin p 52
###xml 101 102 101 102 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 552 553 546 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sup>
###xml 744 748 738 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Wolstencroft1">[25]</xref>
###xml 1349 1350 1334 1335 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1351 1352 1336 1337 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1801 1803 1780 1782 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 1898 1903 1877 1882 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 636 643 <span type="species:ncbi:9606">patient</span>
###xml 704 709 <span type="species:ncbi:10090">mouse</span>
###xml 797 802 <span type="species:ncbi:10090">mouse</span>
###xml 813 819 <span type="species:ncbi:10090">Murine</span>
###xml 870 875 <span type="species:ncbi:10090">mouse</span>
###xml 998 1003 <span type="species:ncbi:10090">mouse</span>
###xml 1035 1040 <span type="species:ncbi:10090">Mouse</span>
###xml 1075 1080 <span type="species:ncbi:10090">mouse</span>
###xml 1426 1432 <span type="species:ncbi:9986">rabbit</span>
###xml 1442 1448 <span type="species:ncbi:9986">rabbit</span>
HeLa cell pellets were prepared in RSB100 lysis buffer (20 mM Tris-HCl pH 7.4 100 mM NaCl, 25 mM MgCl2, Triton x100 0.5%) and centrifuged at 10,000 g for 5 min at 4degreesC. Samples were sonicated and boiled in loading dye then resolved in a 10% SDS-PAGE 20 cmx10 cm BioRad Protean xi Glass plates using Protean 2000. Resolved proteins were then transferred to PVDF (Immoblion) at 200 mAmps for 400 minutes in Towbins (24 mM Tris base, 192 mM glycine, 20% methanol (v/v)). Western blots were blocked overnight in 5% Casein and Tris-buffered Saline (TBST) (90 mM Tris-HCl, 10 mM KCl, 547 mM NaCl, 2% Tween (v/v) (Acros)) pH 7.5. Primary patient fibroblast western blots were probed with 1:100 dilution of mouse anti-SMN monoclonal antibody, 4B7 [25], and visualized with a HRP-conjugated secondary mouse antibody. Murine western blots were probed with 1:1000 dilution of mouse anti-SMN (BD Biosciences) and were produced using 1:1 mixture of Peirce West Pico reagent. Cross reaction with endogenous mouse heavy and light chain antibody Mouse TrueBlottrade mark ULTRA HRP anti-mouse IgG (eBioscience) was used at 1:10 000 in 5% skim milk. Images were captured and quantitated using a Fuji Imager LAS 3000 at 75% of total resolution 10-30 second exposure and Multi-Gauge V2.3 system. To control for loading error the westerns were then stripped using H2O2 for 15-20 minutes at room temperature and re-probed with anti-beta-actin rabbit and anti-rabbit HRP. Western blots were repeated in quadruplicate to confirm 2-tail t-test statistical significance of the increase in SMN protein. To normalize within experiments, SMN induction is determined as (SMN:beta-actin) and between experiments SMN levels is normalized to GM3813 values (triplicate mean set to 1). SMN protein induction was measured using pIn711 ASO as baseline, and fold change over pM13 alone (triplicate mean set to 1) as expressions of trans-splicing efficiency.
###end p 52
###begin title 53
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro snRNP assembly reactions
###end title 53
###begin p 54
###xml 56 70 52 66 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AUUUGUGG-3&#8242;</named-content>
###xml 122 126 118 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Shpargel1">[26]</xref>
###xml 241 244 233 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Eco</italic>
###xml 308 312 300 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATAC</sup>
###xml 480 484 472 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATAC</sup>
###xml 577 638 569 630 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GATCGATCTAATACGACTCACTATAGGGAGAATTCAAAAAGGCTTCTGTCGTGAG-3&#8242;</named-content>
###xml 651 708 643 700 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GATCGATCGGATCTAAATCCACTGTGATATCTTCTCAAAGGGCGCCGGGACCAA-3&#8242;</named-content>
###xml 720 724 712 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATAC</sup>
###xml 944 946 936 938 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 1644 1648 1610 1614 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATAC</sup>
###xml 1759 1762 1715 1718 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">200</sup>
###xml 2530 2532 2466 2468 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;S</sup>
###xml 2787 2789 2723 2725 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 2792 2794 2728 2730 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 2933 2935 2869 2871 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 1573 1578 <span type="species:ncbi:4932">Yeast</span>
###xml 2018 2023 <span type="species:ncbi:10090">Mouse</span>
Cloned U1 snRNA (DeltaSm) cDNA has the Smith core site (5'-AUUUGUGG-3') sequence deleted to inhibit non-specific products [26]. The U1 snRNA (WT and DeltaSm) was in vitro transcribed using the Maxi-prep (Invitrogen) plasmid pT7 cleaved with EcoRI for 3 hours and cleaned up with PCR columns (Invitrogen). U11ATAC snRNA was synthesized with mature post-transcriptional modification sequences and cloned into pGA4 (GENEART) flanked by T7 sequences. Transcriptionally competent snRNAATAC templates were created with primers and high fidelity PCR amplification (Roche). U11FWD #1 (5'-GATCGATCTAATACGACTCACTATAGGGAGAATTCAAAAAGGCTTCTGTCGTGAG-3') U11REV #1 (GATCGATCGGATCTAAATCCACTGTGATATCTTCTCAAAGGGCGCCGGGACCAA-3') The T7-U11ATAC PCR product was PCR purified and used in subsequent transcription reactions as a template. snRNA transcription reactions: 10 units of T7 RNA polymerase HC (Ambion), ARCA-Methyl cap (Ambion) and rNTPs supplemented with P32 labeled rUTP was incubated for 30 minutes at 30degreesC. Cells were harvested and lysed in on ice via fresh Reconstitution Buffer (20 mM Hepes-KOH pH 7.9, 50 mM KCl, 5 mM MgCl2, 0.2 mM EDTA, 0.01% Triton x100). Cytoplasmic and nuclear fractioning was accomplished by centrifugation at 1000 rpm for 15 minutes at 4degreesC. The S100 fraction was removed and (7x) EDTA free protease inhibitor cocktail (Roche) added to preserve the SMN complex. Assembly of the Sm cores occurred for 30 minutes at 30degreesC using 20U of RNAsin (Promega) added to 50 microg total of S100 extract at final concentration of 2.5 mM ATP, 1.0 microg Yeast tRNA, U1 snRNA (100,000 cpm). For the general assembly in the U11ATACsnRNA 75 microg total extract was required for 60 minutes at 30degreesC. Following assembly, 350 uL of DEPC-RSB200 buffer was used in the initial immunoprecipation (IP) steps via primary bead fractions Protein G Plus/Protein A Agarose suspension with PBS (Oncogene) pre-blocked with 25 microg of whole HeLa cell extracts. Bead fractions are pre-incubated with 1 uL anti-Mouse Y12 mono-clonal antibody (Lab Vision) per 50 microL stock slurry volume. Radio-IPs were processed at 4degreesC to reduce signal loss and washed at 25degreesC. UsnRNP and beads were denatured in (5x) formamide loading dye and run on an 8% acrylamide TBE-Urea gel (45 mM Tris-borate, 1 mM EDTA, 7M Urea). Quantitative measurements of snRNP products were derived after a 30-45 minutes exposure on a phospho-screen (Kodak). Bands were imaged using Fuji-Imager FLA5000 and Image Reader FLA5000 V2.0 software (IP-S mode) normalized to background. The Fuji-imager results were correlated to excised bands via scintillation counter output averaged over three rounds of counts per minute. Within experiments the capacity to assemble snRNPs is determined by the ratio of U1WT:U1KO. Between experiments, comparisons were determined by normalization to GM3813 values (set to 1) and above the assembly baseline of ASO pIn711 transfections. GM3813/3814 fibroblasts were included in the experiment up to the fourth passage post cryo-preservation rescue to avoid artificial selection of SMN positive populations.
###end p 54
###begin title 55
###xml 41 45 <span type="species:ncbi:10090">mice</span>
Intracerebroventricular injection of SMA mice
###end title 55
###begin p 56
###xml 376 380 366 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mSMN</italic>
###xml 386 413 376 403 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCAGCTGTGCTCGACGTTGTC-3&#8242;</named-content>
###xml 416 420 406 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mSMN</italic>
###xml 426 453 416 443 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TAAGAAAGCCTCAATGTGCTCAAG</named-content>
###xml 457 461 447 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 467 495 457 485 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCGATAGAGTGAGACTCCATCT-3&#8242;</named-content>
###xml 499 503 489 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 509 539 499 529 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GACATAGAGGTCTGATCTTTAGCT-3&#8242;</named-content>
###xml 541 545 531 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003468-Butchbach1">[27]</xref>
###xml 1398 1405 1348 1355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 1667 1674 1617 1624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 2379 2380 2325 2326 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 2435 2436 2377 2378 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 2515 2522 2457 2464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 2530 2535 2472 2477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 4 9 <span type="species:ncbi:10090">mouse</span>
###xml 1019 1023 <span type="species:ncbi:10090">Mice</span>
###xml 2523 2529 <span type="species:ncbi:10090">murine</span>
###xml 2596 2601 <span type="species:ncbi:9606">human</span>
SMA mouse were genotyped PND 0 via tail clip. Frozen tails were prepared using a binary HOTShot method: 90degreesC for 10 minutes alkaline lysis solution (25 mM NaOH 0.2 mM disodium EDTA) and Trizma base neutralizing solution (40 mM Tris-HCl). 1.5-2.0 microL input tail solution was added to PCR reactions containing previously described, yet renamed for clarity, primer sets mSMN FWD (5'-GCAGCTGTGCTCGACGTTGTC-3'), mSMN REV (5'-TAAGAAAGCCTCAATGTGCTCAAG), hSMN2 FWD (5'-GCGATAGAGTGAGACTCCATCT-3'), hSMN2 REV (5'-GACATAGAGGTCTGATCTTTAGCT-3') [27]. PND 2 neonates were immobilized via cryo-anesthesia and injected using microL calibrated sterilized glass micropipette 0.25 mm lateral to the sagittal suture and 0.50-0.75 mm rostral to the neonatal coronary suture. The needles were inserted perpendicular to the skull surface using a fiber-optic light (Boyce Scientific Inc.) to illuminate pertinent anatomical structures. Needles were removed after 15 seconds of discontinuation of plunger movement to prevent backflow. Mice recovered in 5-10 minutes in a warmed container until movement and general response was restored. Injection stock solutions contained and final volumes include: D-(+)-glucose 20% (w/v) (1 microL) (Sigma), trypan blue (0.4%) saline (1 microL) (Sigma), plasmid (approximately5 microg/microL) (2 microL), 25 kDa linear PEI homopolymer (150 mM) (1 microL) (Polysciences, Inc.). In vivo plasmids prepared with endo-toxin free Maxi-prep (QIAgen) were analyzed for purity and superhelicity in 4% agarose gels and NanoDrop quantifications. Control mock in vivo transfections contain glucose, trypan blue saline, 25 kDa PEI and do not contain plasmid. In vivo western and northern blot was performed by dissecting the CNS with microsurgical technique via Roboz RS-5600 (Roboz Surgical Instrument Co., Inc.) and gross disassociation performed by passing tissue re-suspended in PBS through a 18-gauge needle and aliquot into individual tubes, then snap-frozen in liquid nitrogen. Total spinal cord RNA was collected by TRIzol (Invitrogen) and the final pellet resuspended in 30 microL of PrepSolution (40 mM PIPES pH 6.8, 1 mM EDTA, 250 mM NaCl, 80% (v/v) deionized formamide). The RNA was blotted by vacuum with BioDot SF (BioRad) seeding on 9x12 cm Zeta probe membranes (BioRad). GFP probes were created by Klenow fragment synthesis with Easytides dATP creating 108 cpm/microg product used at a final concentration of 106 cpm/mL in the hybridization buffer (500 mM Na2PO4 pH 7.2, 1% SDS, 1 mM EDTA). In vivo murine trans-splicing RT-PCR was performed with the previously reported "human-specific" Exon 4 35-55 forward (Hua et al. 2008) combined with the standard M13 reverse primer.
###end p 56
###begin title 57
Statistical analysis
###end title 57
###begin p 58
###xml 661 663 655 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 527 531 <span type="species:ncbi:10090">mice</span>
###xml 664 669 <span type="species:ncbi:10090">mouse</span>
Student t-tests were utilized to gauge significance between two results via 2-tailed regression analysis. Levels of significance were set to p</=0.05 for a single treatment regiment and repeated in triplicate to determine mean and +/-standard deviation values. Statistical values are represented as the inset graphs and error bars indicate +/-s.d. for the averages. The data collected was normalized internally to 1 using a base line controls indicated in the above method sections. This approach is justified by the number of mice compared, involved in treatment versus mock, and relative fold change in the overall protein expression post-treatments using SMNKO mouse mock as basal.
###end p 58
###begin title 59
Supporting Information
###end title 59
###begin p 60
Summary of SMN2 trans-splicing and intron 7 ASO-tiling screen demonstrates specificity of ASO-In711 effect. (A) Graphical depiction of intron 7 ASO targets. ASO sequences are identified at the beginning of the individual string, written 5'-3'. Capitalized sequence indicates exon 8 sequences with the 3' splice site defined in red. The bars located directly below illustrate the effects on the trans-splicing product by the respective colors. Black lines indicate neutral effects, red lines indicate negative influences, and green lines represent increased trans-splicing. (B) Summary of even numbered intron 7 ASO screen demonstrates no effect. HeLa cells were triple-transfected with plasmids expressing pM13 1.0 microg, a minigene SMN2 (lanes a-h) 1.25 microg and ASO pIn72-pIn712 (lanes c-h) 1.0 microg and RNA harvested at 48 hrs. Reverse transcriptase PCR gel is displayed with GAPDH normalization control. pIn71 negative control serves to normalized between ASO experiments. (C) Summary of odd numbered intron 7 ASO screen identifies pIn711 ASO as a potent enhancer of trans-splicing. HeLa cells were triple-transfected with plasmids expressing pM13 1.0 microg, a minigene pSMN2 (lanes a-d) 1.25 microg and ASO pIn71-5, pIn77-11 (lanes b-d) 1.0 microg for blots respectively and RNA harvested at 48 hrs. Reverse transcriptase PCR gel is displayed with GAPDH normalization control. pM13 controls for basal trans-splicing. (D) HeLa cells were triple-transfected with plasmids expressing a minigene SMN2 (lanes a-d) 1.25 microg, pM13 (lanes b-e) 1.0 microg, a negative control scrambled ASO-tsRNA vector pMU3KO (lane a) 1.0 microg and ASO-tsRNA DNA recombination control transfection with pM13 and pIn711 (lane e) 1.0 microg minus pSMN2. RNA harvested at 48 hrs. Reverse transcriptase PCR gel is displayed with GAPDH normalization control. pM13 controls for basal trans-splicing (lane c).
###end p 60
###begin p 61
(2.16 MB TIF)
###end p 61
###begin p 62
Click here for additional data file.
###end p 62
###begin p 63
###xml 69 76 <span type="species:ncbi:9606">patient</span>
The ASO-tsRNA mechanism can be applied to heterologous contexts. SMA patient fibroblasts co-transfected with a trans-splicing RNA that targets SMN intron 3 containing SMN exons 4-7 written as "pMU2-tsRNAEX4" (lanes b-f) (0.25 microg) with increasing concentrations of enhancing ASO directed toward the intron 4/exon 5 splice site "pMU2-In411" (c-f) (0.25 microg, 0.50 microg, 0.75 microg, 1.0 microg) produced increased trans-splicing. Reverse transcriptase PCR gel is displayed with GAPDH normalization control. Lane a represents negative control omitting RT polymerase, lane b is base line trans-splicing for pMU2-tsRNAEX4.
###end p 63
###begin p 64
(1.65 MB DOC)
###end p 64
###begin p 65
Click here for additional data file.
###end p 65
###begin title 66
References
###end title 66
###begin article-title 67
Messenger RNA reprogramming by spliceosome-mediated RNA trans-splicing.
###end article-title 67
###begin article-title 68
Alternative splicing in disease and therapy.
###end article-title 68
###begin article-title 69
SMaRT technology enables gene expression repair in skin gene therapy.
###end article-title 69
###begin article-title 70
Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies.
###end article-title 70
###begin article-title 71
5' trans-splicing repair of the PLEC1 gene.
###end article-title 71
###begin article-title 72
Correction of DNA protein kinase deficiency by spliceosome-mediated RNA trans-splicing and sleeping beauty transposon delivery.
###end article-title 72
###begin article-title 73
Modulating the expression of disease genes with RNA-based therapy.
###end article-title 73
###begin article-title 74
The neurobiology of childhood spinal muscular atrophy.
###end article-title 74
###begin article-title 75
The changing natural history of spinal muscular atrophy type 1.
###end article-title 75
###begin article-title 76
Identification and characterization of a spinal muscular atrophy- determining gene.
###end article-title 76
###begin article-title 77
Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1.
###end article-title 77
###begin article-title 78
A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy.
###end article-title 78
###begin article-title 79
Therapeutics development for spinal muscular atrophy.
###end article-title 79
###begin article-title 80
Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector.
###end article-title 80
###begin article-title 81
Restoration of SMN function: delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing.
###end article-title 81
###begin article-title 82
Genetic conversion of an SMN2 gene to SMN1: a novel approach to the treatment of spinal muscular atrophy.
###end article-title 82
###begin article-title 83
Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon.
###end article-title 83
###begin article-title 84
###xml 100 104 <span type="species:ncbi:10090">Mice</span>
Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice.
###end article-title 84
###begin article-title 85
Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs.
###end article-title 85
###begin article-title 86
Spinal Muscular Atrophy: SMN2 Pre-mRNA Splicing Corrected by a U7 snRNA Derivative Carrying a Splicing Enhancer Sequence.
###end article-title 86
###begin article-title 87
A slow RNA polymerase II affects alternative splicing in vivo.
###end article-title 87
###begin article-title 88
Chaperoning ribonucleoprotein biogenesis in health and disease.
###end article-title 88
###begin article-title 89
Ribonucleoprotein Assembly Defects Correlate with Spinal Muscular Atrophy Severity and Preferentially Affect a Subset of Spliceosomal snRNPs.
###end article-title 89
###begin article-title 90
###xml 103 107 <span type="species:ncbi:10090">mice</span>
SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN.
###end article-title 90
###begin article-title 91
A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels.
###end article-title 91
###begin article-title 92
Gemin proteins are required for efficient assembly of Sm-class ribonucleoproteins.
###end article-title 92
###begin article-title 93
###xml 42 47 <span type="species:ncbi:10090">mouse</span>
Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy.
###end article-title 93
###begin p 94
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 94
###begin p 95
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: T.H.C. is supported by Training Grant T32 GM008396. This work was funded by grants from the MDA (M.S.), FightSMA (C.L.L.) and the National Institutes of Health (C.L.L, R01 NS41584; R01 HD054413).
###end p 95

